2-Ethyl-5-isopropyl-pyrrol | 13138-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-Ethyl-5-isopropyl-pyrrol
• 英文别名: 2-ethyl-5-isopropyl-pyrrole；2-Aethyl-5-isopropyl-pyrrol；2-ethyl-5-propan-2-yl-1H-pyrrole
• CAS: 13138-19-7
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: LGSFUHPSKVXCMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-Ethyl-5-isopropyl-pyrrol 在 1,4-二氧六环 、 镍 作用下， 190.0 ℃ 、14.71 MPa 条件下， 生成 2-ethyl-5-isopropyl-pyrrolidine
  参考文献：
  名称：

  Concerning the Structure of “Acetonepyrrole”

  摘要：

  DOI：

  10.1021/ja01617a056
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 溴乙烷 作用下， 生成 2-Ethyl-5-isopropyl-pyrrol
  参考文献：
  名称：

  Concerning the Structure of “Acetonepyrrole”

  摘要：

  DOI：

  10.1021/ja01617a056

文献信息

• NEW 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS
  申请人：TREU Matthias

  公开号：US20130190305A1

  公开（公告）日：2013-07-25

  The present invention encompasses compounds of general formula (I) wherein the groups R 1 to R 6 , A, B, C, n, p, q and r are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

  本发明涵盖了一般式（I）的化合物， 其中R 1 到R 6 ，A，B，C，n，p，q和r的定义如权利要求书中所述， 适用于治疗以细胞过度或异常增殖为特征的疾病，包含这种化合物的药物制剂以及它们作为药物的用途。
• The synthesis of pyrroles via acceptorless dehydrogenative condensation of secondary alcohols and 1,2-amino alcohols mediated by a robust and reusable catalyst based on nanometer-sized iridium particles
  作者：Daniel Forberg、Johannes Obenauf、Martin Friedrich、Sven-Martin Hühne、Werner Mader、Günter Motz、Rhett Kempe

  DOI：10.1039/c4cy01018c

  日期：——

  Pyrroles are important compounds with several applications in medicine and material science. They can be synthesized sustainably from secondary alcohols and amino alcohols. Hydrogen and water are liberated in the course of this reaction. Here, we present that this sustainable catalytic pyrrole synthesis can be mediated efficiently by a novel iridium nanoparticle catalyst. The catalyst synthesis starts

  吡咯是重要的化合物，在医学和材料科学中有多种应用。它们可以由仲醇和氨基醇可持续地合成。在该反应过程中释放出氢气和水。在这里，我们目前可以通过新型铱纳米粒子催化剂有效地介导这种可持续的催化吡咯合成。催化剂的合成从分子前体，N-配体稳定的Ir络合物和市售的聚硅氮烷开始。实现了纳米级铱粒子的生成（由于载体中存在N原子）。载体的坚固性质允许催化剂的再利用。通过合成23种吡咯衍生物（分离产率高达93％）验证了反应的范围。因此，有吸引力的官能团耐受性（例如胺和烯烃）。市售的非均相Ir催化剂在该吡咯合成中效率低下，并且在可重复使用性方面受到极大限制。
• [EN] PYRIDYLTRIAZOLES<br/>[FR] PYRIDYLTRIAZOLES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011117382A1

  公开（公告）日：2011-09-29

  The present invention encompasses compounds of general formula (1) wherein the groups R0 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

  本发明涵盖了一般式（1）中的化合物，其中基团R0至R3和L的定义如索赔1中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，包括含有这种化合物的药物制剂以及它们作为药物的用途。
• Sulfonamide containing compounds for treatment of inflammatory disorders
  申请人：Weingarten M. David

  公开号：US20090270454A1

  公开（公告）日：2009-10-29

  Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH 2 — or —CH 2 —CH 2 —; Z is selected from S(O) m or Se(O) m and m is 0, 1 or 2; R 1 is optionally substituted heteroaryl or heterocyclic; R 2 is selected from the group consisting of hydrogen, C 1 -C 6 straight alkyl, and C 1 -C 6 branched alkyl, wherein all may be optionally substituted; and R 3 and R 4 are alkyl.

  提供了化合物、药物组合物及治疗或预防炎症状况，特别是哮喘的方法。该化合物属于一般式I，或其药学上可接受的盐、酯、前药或衍生物：其中，X和Y独立地选择自—CH2—或—CH2—CH2—；Z选择自S(O)m或Se(O)m，m为0、1或2；R1为可选择的取代杂环芳基或杂环基；R2选择自氢、C1-C6直链烷基和C1-C6支链烷基，其中所有基团均可选择性地取代；R3和R4为烷基。
• PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES
  申请人：Ettmayer Peter

  公开号：US20120046270A1

  公开（公告）日：2012-02-23

  The present invention encompasses compounds of general formula (1), wherein the groups R 1 to R 4 , X 1 , X 2 , X 3 , X 4 , X 5 , Q, L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

  本发明涵盖了通式（1）的化合物，其中R1到R4，X1，X2，X3，X4，X5，Q，L1和L2的基团如权利要求1中所定义，这些化合物适用于治疗由细胞过度增殖或异常增殖所特征的疾病，以及这些化合物的制药制剂和配方。